Business
New Vedanta VE202 Data Presented at UEG Week
New Vedanta VE202 Data Presented at UEG Week.
About this update from Puretech Health Plc
[{"type":"text","content":"\n \n \n \n RNS Number : 7110B\n PureTech Health PLC\n 12 October 2020\n \n \n \n \n 12 October 2020\n \n \n PureTech Health plc\n \n \n \n \n \n \n PureTech Founded Entity \n \n \n Vedanta Biosciences \n \n \n Announces Additional \n \n \n Pharmacokinetics \n \n \n Data from Phase 1 Study of VE202 for Inflammatory Bowel Disease to be Presented at United European Gastroenterology Week 2020\n \n \n \n \n \n \n Data to be presented showing VE202 microbiome-derived bacterial strains rapidly, abundantly and durably colonise the gut of healthy volunteers \n \n \n \n \n \n \n \n PureTech Health plc\n \n \n (LSE: PRTC) (\"PureTech\"\n \n or the \"Company\"), a clinical-stage biotherapeutics company dedicated to discovering, developing and commercialising highly differentiated medicines for devastating diseases, is pleased to note that its Founded Entity, Vedanta Biosciences, today announced t\n \n hat additional \n pharmacokinetics data \n from a Phase 1 clinical study of VE202 in healthy volunteers will be presented by Janssen Research & Development, LLC, at United European Gastroenterology (UEG) Week 2020, held virtually from October 11-13. \n \n \n \n \n \n Topline data from placebo-controlled Phase 1 studies were announced in June, which reported that VE202 was generally well-tolerated at all doses studied. The new UEG Week data presentation focuses on the \n kinetics and durability of colonisation from an 11-strain consortium of VE202 under various dosing and pre-treatment regimens.\n \n \n \n \n \n Bharatt Chowrira, JD, PhD, PureTech's president and chief of business and strategy, said: \"These additional Phase 1 data are important, as sustained and durable colonisation of the healthy human gut suggests that VE202 is having the desired effect. The findings further validate Vedanta's unique and differentiated approach to developing microbiome-based products and support the potential of VE202 as a novel treatment for inflammatory bowel disease (IBD). We're pleased that Vedanta will continue to progress the programme into a Phase 2 study in patients with IBD.\"\n \n \n \n \n \n \n \n The full text of the announcement from Vedanta Biosciences is as follows:\n \n \n \n \n \n \n Vedanta Biosciences Announces Additional \n \n \n Pharmacokinetics \n \n \n Data from Phase 1 Study of VE20...